E2F transcription factor-1 modulates expression of glutamine metabolic genes in mouse embryonic fibroblasts and uterine sarcoma cells.

E2F1 Glutamine MYC SLC1A5 Uterine sarcoma cancer metabolism

Journal

Biochimica et biophysica acta. Molecular cell research
ISSN: 1879-2596
Titre abrégé: Biochim Biophys Acta Mol Cell Res
Pays: Netherlands
ID NLM: 101731731

Informations de publication

Date de publication:
03 Apr 2024
Historique:
received: 27 10 2023
revised: 12 03 2024
accepted: 27 03 2024
medline: 6 4 2024
pubmed: 6 4 2024
entrez: 5 4 2024
Statut: aheadofprint

Résumé

Metabolic reprogramming is considered as a hallmark of cancer and is clinically exploited as a novel target for therapy. The E2F transcription factor-1 (E2F1) regulates various cellular processes, including proliferative and metabolic pathways, and acts, depending on the cellular and molecular context, as an oncogene or tumor suppressor. The latter is evident by the observation that E2f1-knockout mice develop spontaneous tumors, including uterine sarcomas. This dual role warrants a detailed investigation of how E2F1 loss impacts metabolic pathways related to cancer progression. Our data indicate that E2F1 binds to the promoter of several glutamine metabolism-related genes. Interestingly, the expression of genes in the glutamine metabolic pathway were increased in mouse embryonic fibroblasts (MEFs) lacking E2F1. In addition, we confirm that E2f1

Identifiants

DOI: 10.1016/j.bbamcr.2024.119721 PMID: 38580088
pubmed: 38580088
pii: S0167-4889(24)00064-8
doi: 10.1016/j.bbamcr.2024.119721
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119721

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no competing interests, except A.G., who is an employee of Société des Produits Nestlé S.A.

Auteurs

Katharina Huber (K)

Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Albert Giralt (A)

Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland.

René Dreos (R)

Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland.

Helene Michenthaler (H)

Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Division of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria.

Sarah Geller (S)

Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland.

Valentin Barquissau (V)

Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland.

Dorian V Ziegler (DV)

Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland.

Daniele Tavernari (D)

Department of Computational Biology, University of Lausanne, Lausanne, Switzerland; Swiss Cancer Center Léman, Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland.

Hector Gallart-Ayala (H)

Metabolomics Unit, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.

Katarina Krajina (K)

Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Katharina Jonas (K)

Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Giovanni Ciriello (G)

Department of Computational Biology, University of Lausanne, Lausanne, Switzerland; Swiss Cancer Center Léman, Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland.

Julijana Ivanisevic (J)

Metabolomics Unit, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.

Andreas Prokesch (A)

Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Division of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria; BioTechMed-Graz, Graz, Austria.

Martin Pichler (M)

Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; Translational Oncology, II. Med. Clinics, University Hospital of Augsburg, Augsburg, Germany.

Lluis Fajas (L)

Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland. Electronic address: lluis.fajas@unil.ch.

Classifications MeSH